Henry Schein Inc. (HSIC) shares plummeted 5.01% in intraday trading on Tuesday, February 25th, following the company's disappointing fourth-quarter earnings results and weak guidance for 2025, reflecting the impact of persistent inflation and tepid demand for dental products.
The medical and dental products distributor reported adjusted earnings per share (EPS) of $1.19 for the fourth quarter, missing analyst estimates of $1.21. Revenue for the quarter came in at $3.19 billion, falling short of the expected $3.27 billion, as higher prices squeezed customer budgets, forcing them to cancel or postpone non-urgent procedures.
For the full year 2025, Henry Schein forecasted adjusted EPS in the range of $4.80 to $4.94, below Wall Street's estimates of $4.99. The company also expects annual sales growth of only 2% to 4%, lower than the projected $13.19 billion, citing tepid demand amid persistent inflation in the dental and medical end-markets.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。